Cardiovascular risk planning and reduction for men with prostate cancer
Official title: Cardiovascular Risk Prediction and Reduction in Men with Prostate Cancer
Funded at University of Pennsylvania · NIH-11627340 · Data updated 2026-11-12
A program to better predict and reduce heart disease risk in men treated for prostate cancer, especially older patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pennsylvania NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project start | September 25, 2025 |
| Project end | August 31, 2029 |
| Funding year | 2026 |
| Award (this year) | $21,340 |
| NIH project number | 3R01HL182015-02S1 |
| Project ID | NIH-11627340 on NIH RePORTER |
Who could benefit from this research
✓Could help
Men with non-metastatic prostate cancer, particularly older adults undergoing or after androgen deprivation therapy.
✕Less likely to help
Patients without prostate cancer or without a cardiovascular risk concern may not benefit.
What this research studies
This project focuses on understanding why men with prostate cancer have higher heart-disease risk and how existing tools miss important cancer-related factors. Researchers will develop improved ways to estimate cardiovascular risk that include treatments like androgen deprivation therapy and competing health risks. They will test and refine risk tools to guide personalized prevention and management for individual patients. The goal is to help men stay healthier overall during and after prostate cancer care.
Why it matters
Potential benefit: If successful, patients could receive more personalized heart-disease prevention during prostate cancer treatment, potentially lowering heart-attack risk and improving longevity.
How similar studies have gone: Previous risk tools perform poorly in cancer patients; this project aims to improve on that with cancer-specific considerations.
Where this research is happening
-
University of Pennsylvania
Philadelphia, United States Active
Researchers
- Principal investigator: Ky, Bonnie — University of Pennsylvania
- Study coordinator: Ky, Bonnie
Related research
Other NIH-funded projects on the same topics.
-
Effects of ADT on motivation and emotion in prostate cancer patients
This project looks at how androgen deprivation therapy may affect motivation and mood over time in men with prostate cancer.
-
Causal Protein Markers to Understand and Predict Prostate Cancer Risk in Africans and Europeans
A cancer research project looking at proteins linked to prostate cancer to better understand why it happens and how risk differs between African and European populations.
-
Ethical multimodal AI platform to improve prostate cancer detection with ultrasound
A patient-friendly AI system uses ultrasound and MRI information to help doctors better find prostate cancer, aiming to improve accuracy and access.
-
Characterizing epigenetic targets in prostate cancer to help AR-driven cancer
A research project at MD Anderson aims to understand how epigenetic factors shape androgen receptor signaling in prostate cancer to find new ways to treat resistant forms of the disease.
-
AR and RNA-binding in prostate cancer resistance
A cancer research grant exploring how the androgen receptor’s interaction with RNA may drive treatment resistance in prostate cancer, with potential to guide new therapies.
-
New microfluidic platform to test prostate cancer drugs using patient tumor cells
A new microfluidic, open platform uses patient-derived prostate cancer cells to create multi-culture tumor models that could better predict whether a treatment will work for Veterans.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.